Oruka Therapeutics (DE:HQ1)

FRANKFURT:HQ1

HQ1

Oruka Therapeutics

RESEARCH TOOLSreports

Oruka Therapeutics (HQ1) Price & Analysis

0 Followers

HQ1 Stock Chart & Stats

€54.50

-€0.90(-4.71%)

At close: Jan 08 4:00 PM EST

€54.50

-€0.90(-4.71%)

Day’s Range― - ―

52-Week Range€6.00 - €54.50

Previous CloseN/A

Volume0.00

Average Volume (3M)56.00

Market Cap

€2.63B

Enterprise Value€2.34B

Total Cash (Recent Filing)€337.04M

Total Debt (Recent Filing)€1.93M

Price to Earnings (P/E)―

Beta0.29

Next Earnings

May 20, 2026

EPS Estimate

-0.47

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding49,542,690

10 Day Avg. Volume3

30 Day Avg. Volume56

Financial Highlights & Ratios

PEG Ratio0.24

Price to Book (P/B)2.93

Price to Sales (P/S)0.00

P/FCF Ratio-15.64

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€61.16

Price Target Upside12.22% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-2

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Development ProgressAnalyst notes accelerated reporting of initial efficacy results for the lead psoriasis candidate after rapid enrollment, which could reduce development uncertainty and increase investor confidence if outcomes are strong.

Dosing Convenience And Commercial AppealAnalyst highlights that an extended dosing profile with infrequent subcutaneous injections could offer a clear convenience advantage over current biologics and drive higher patient and physician adoption.

Pipeline Expansion And Multiple MilestonesAnalyst points to the addition of mid-stage programs, including a progressing second candidate and planned studies in hidradenitis suppurativa, as sources of multiple upcoming clinical readouts that could materially affect the company’s outlook.

Bears Say

Financial Runway And Funding RiskAnalyst warns that cash resources appear limited relative to spending, creating the risk of future financing needs that could dilute shareholders if capital is raised under pressure.

Limited Clinical EvidenceAnalyst cautions that the strongest efficacy signals come from a small, single-center study, which limits confidence until larger, randomized trials replicate the results.

Market Skepticism And Short InterestAnalyst notes notable short interest as an indicator of market skepticism that could weigh on the stock and amplify downside absent clear positive clinical or financial developments.

Oruka Therapeutics News

Oruka Therapeutics price target raised to $78 from $50 at Barclays

Barclays raised the firm’s price target on Oruka Therapeutics (ORKA) to $78 from $50 and keeps an Overweight...

3d ago

ORKA

Oruka Therapeutics price target raised to $75 from $50 at UBS

UBS raised the firm’s price target on Oruka Therapeutics (ORKA) to $75 from $50 and keeps a Buy...

4d ago

ORKA

Oruka Therapeutics price target raised to $125 from $60 at Guggenheim

Guggenheim raised the firm’s price target on Oruka Therapeutics (ORKA) to $125 from $60 and keeps a Buy...

4d ago

ABBV

ORKA

Oruka Therapeutics files $1B mixed securities shelf

16:12 EDT Oruka Therapeutics (ORKA) files $1B mixed securities shelf Published first on TheFly – the ultimate source...

7d ago

ORKA

Oruka Therapeutics price target raised to $86 from $58 at Leerink

Leerink raised the firm’s price target on Oruka Therapeutics (ORKA) to $86 from $58 and keeps an Outperform...

25d ago

ORKA

Oruka Therapeutics price target raised to $72 from $47 at Stifel

Stifel raised the firm’s price target on Oruka Therapeutics (ORKA) to $72 from $47 and keeps a Buy...

28d ago

ORKA

Oruka Therapeutics price target raised to $50 from $48 at Barclays

Barclays analyst Etzer Darout raised the firm’s price target on Oruka Therapeutics (ORKA) to $50 from $48 and...

28d ago

ORKA

Oruka Therapeutics reports Q4 EPS (45c), consensus (62c)

“We are very pleased with the progress of both our co-lead programs as we advance into what could...

28d ago

ORKA

ORKA-001 Phase 1 Completion: What Oruka’s First-in-Human Milestone Means for Investors

Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. The study, titled “Phase 1, First-in-human,...

9d ago

ORKA

Oruka’s ORKA-001 Extension Study Builds Long-Term Case in Psoriasis Market

Oruka Therapeutics, Inc. ($ORKA) announced an update on their ongoing clinical study. Oruka Therapeutics, Inc. is running an...

1M ago

ORKA

Is ORKA a Buy, Before Earnings?

Oruka Therapeutics, Inc. (ORKA) is scheduled to report 4th quarter earnings on 03/05/2026. Regarding Q4 estimates, Wall Street...

1M ago

ORKA

Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy

Clear Street analyst Kaveri Pohlman believes AbbVie’s (ABBV) plan to bring an extended half-life anti-IL-23 mAb into the...

2M ago

GSK

ABBV

Oruka Therapeutics price target raised to $45 from $42 at Wedbush

Wedbush raised the firm’s price target on Oruka Therapeutics (ORKA) to $45 from $42 and keeps an Outperform...

3M ago

ORKA

Oruka Therapeutics: Long-Acting IL-17 Platform Drives Upgraded Valuation and Buy Rating

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics and increased the price target...

3M ago

ORKA

HQ1 FAQ

What was Oruka Therapeutics’s price range in the past 12 months?

Oruka Therapeutics lowest stock price was €6.00 and its highest was €54.50 in the past 12 months.

What is Oruka Therapeutics’s market cap?

Oruka Therapeutics’s market cap is €2.63B.

When is Oruka Therapeutics’s upcoming earnings report date?

Oruka Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 40 days.

How were Oruka Therapeutics’s earnings last quarter?

Oruka Therapeutics released its earnings results on Mar 12, 2026. The company reported -€0.39 earnings per share for the quarter, beating the consensus estimate of -€0.552 by €0.161.

Is Oruka Therapeutics overvalued?

According to Wall Street analysts Oruka Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oruka Therapeutics pay dividends?

Oruka Therapeutics does not currently pay dividends.

What is Oruka Therapeutics’s EPS estimate?

Oruka Therapeutics’s EPS estimate is -0.47.

How many shares outstanding does Oruka Therapeutics have?

Oruka Therapeutics has 49,542,690 shares outstanding.

What happened to Oruka Therapeutics’s price movement after its last earnings report?

Oruka Therapeutics reported an EPS of -€0.39 in its last earnings report, beating expectations of -€0.552. Following the earnings report the stock price went down -7.483%.

Which hedge fund is a major shareholder of Oruka Therapeutics?

Currently, no hedge funds are holding shares in DE:HQ1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Oruka Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-25.30%

Trailing 12-Months

Asset Growth

23.38%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oruka Therapeutics

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Oruka Therapeutics (HQ1) Earnings & Revenues

Historic Earnings Reports

HQ1 Stock 12 Month Forecast

Average Price Target

€61.16

▲(12.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"€8","33":"€33","58":"€58","83":"€83","108":"€108"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":107.1736925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€107.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.16045385333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€61.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.2955816,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€34.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,33,58,83,108],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.8,46.828745576923076,51.857491153846155,56.88623673076923,61.914982307692306,66.94372788461538,71.97247346153846,77.00121903846153,82.02996461538461,87.0587101923077,92.08745576923077,97.11620134615384,102.14494692307693,{"y":107.1736925,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.8,43.28926568102564,44.77853136205128,46.26779704307692,47.75706272410256,49.2463284051282,50.735594086153846,52.22485976717948,53.714125448205124,55.203391129230766,56.69265681025641,58.18192249128205,59.671188172307694,{"y":61.16045385333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,41.8,41.222737046153846,40.64547409230769,40.068211138461535,39.490948184615384,38.913685230769225,38.336422276923074,37.75915932307692,37.18189636923077,36.60463341538461,36.02737046153846,35.45010750769231,34.87284455384615,{"y":34.2955816,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >